![]() In 2020, the breath testing segment held the largest share of the market, and is also expected to grow at the fastest rate in the coming years. It is, therefore, estimated that the prevalence of IBS and SIBO will grow significantly in the near future, leading to the increasing diagnosis and eventual market growth.īased on diagnosis, the SIBO diagnostics market is segmented into breath testing, small intestine aspirate and fluid culture test, blood test, and others. Similarly, according to the recent data published in 2020 by the American College of Gastroenterology, ~78% of IBS patients are living with SBIO hence, it is a predominantly evaluated condition. For instance, according to an article, ’Small Intestinal Bacterial Overgrowth: A Case-Based Review’ published in the Journal of Patient-Centered Research and Reviews (JPCRR) in November 2015, 30–85% of adult patients with IBS are likely to develop SIBO. Therefore, the prevalence of SIBO is widely understood and reported worldwide. Technological developments have now allowed the diagnosis of SIBO while diagnosing IBS. Likewise, SIBO shows similar symptoms to IBS. Small intestinal bacterial overgrowth (SIBO) is widely associated with the IBS. The increasing prevalence of IBS across the world is due to the changing lifestyle and dietary habits. Countries such as Japan, China, Russia, South Africa, and the US have a prevalence rate of 2.2%, 2.3%, 5.9%, 5.9%, and 5.3%, respectively. in 2021, most countries have a prevalence rate of 2–6%. According to a research article, ‘Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study’ published by Elsevier Inc. The incidences of IBS are increasing at a significant rate across the world. ![]() Irritable bowel syndrome (IBS) is the commonly diagnosed gastrointestinal disorder with abdominal pain and altered bowel habits resulting with associated symptoms such as bloating, malabsorption, and systemic symptoms. Increasing Prevalence of Irritable Bowel Syndrome (IBS) and SIBO Get more information on this report : Request Free Sample PDF Lucrative Regions for SIBO Diagnostics Market It is estimated that the market is likely to have slower growth rate during the forecast period owing to the restricted health services and lockdown situation caused by COVID-19 pandemic. It also includes COVID-19 impact analysis across all the regions. The report offers insights and in-depth analysis of the SIBO diagnostics market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world. Based on geography, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The SIBO diagnostics market is segmented on the basis of diagnosis, type, and geography. These tests are widely performed in every clinical setting due to their low costs, non-invasively, sufficient accuracy, and reproducibility. The presence of SIBO is generally diagnosed with hydrogen lactulose and glucose breath tests. In worse cases, it may result in real malabsorption syndrome. SIBO results in gastrointestinal IBS-like symptoms, which could be asymptomatic. ![]() It varies highly based on the underlying disorders and microbiota characteristics of patients and organisms. Small intestinal bacterial overgrowth (SIBO) is commonly seen in the presence of one or more predisposing conditions. The SIBO diagnostics market was valued at US$ 138,324.23 thousand in 2020, and it is projected to reach US$ 194,604.51 thousand by 2028 it is expected to grow at a CAGR of 4.4% from 2021 to 2028. ![]() ![]() Minimally Invasive/Non-Invasive Surgery.Aerospace & Defense Systems & Technologies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |